Novo Nordisk A/S (NOV.DE)

EUR 103.14

(-0.33%)

Total Liabilities Summary of Novo Nordisk A/S

  • Novo Nordisk A/S's latest annual total liabilities in 2023 was 27.88 Billion DKK , up 31.82% from previous year.
  • Novo Nordisk A/S's latest quarterly total liabilities in 2024 Q1 was 26.74 Billion DKK , down -3.81% from previous quarter.
  • Novo Nordisk A/S reported annual total liabilities of 21.15 Billion DKK in 2022, up 27.12% from previous year.
  • Novo Nordisk A/S reported annual total liabilities of 16.64 Billion DKK in 2021, up 51.81% from previous year.
  • Novo Nordisk A/S reported quarterly total liabilities of 26.74 Billion DKK for 2024 Q1, down -3.81% from previous quarter.
  • Novo Nordisk A/S reported quarterly total liabilities of 27.88 Billion DKK for 2023 FY, up 31.82% from previous quarter.

Annual Total Liabilities Chart of Novo Nordisk A/S (2023 - 2016)

Historical Annual Total Liabilities of Novo Nordisk A/S (2023 - 2016)

Year Total Liabilities Total Liabilities Growth
2023 27.88 Billion DKK 31.82%
2022 21.15 Billion DKK 27.12%
2021 16.64 Billion DKK 51.81%
2020 10.96 Billion DKK 20.43%
2019 9.1 Billion EUR 15.27%
2018 7.89 Billion EUR 11.91%
2017 7.05 Billion EUR 0.38%
2016 7.02 Billion EUR 0.0%

Peer Total Liabilities Comparison of Novo Nordisk A/S

Name Total Liabilities Total Liabilities Difference
BioNTech SE 2.76 Billion EUR -910.176%
CureVac N.V. 271.53 Million EUR -10169.484%
Biotest Aktiengesellschaft 945.4 Million EUR -2849.535%
Biotest Aktiengesellschaft 945.4 Million EUR -2849.535%
BRAIN Biotech AG 47.92 Million EUR -58086.888%
Formycon AG 387.61 Million EUR -7094.043%
Heidelberg Pharma AG 21.01 Million EUR -132601.616%
Medigene AG 10.65 Million EUR -261730.07%